The text starts here.

News Release

FOR IMMEDIATE RELEASE
July 30, 2004

Eisai's German Pharmaceuticals Marketing Subsidiary
Starts Promotion of AstraZeneca's ENTOCORT (R),
a locally acting Glucocorticosteroid for Inflammatory Bowel Diseases

Eisai Co., Ltd.
Eisai GmbH


Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that Eisai GmbH (hereinafter "EDG", Headquarters: Frankfurt, President: Andreas N. Wiegand), a German subsidiary of Eisai, and AstraZeneca Germany (hereinafter "AZ") entered into a promotion agreement for AZ's ENTOCORT(R) (generic name: budesonide), a locally acting glucocorticosteroid, in the German market. Under the agreement, from August 1, 2004, EDG will solely promote all available presentations: capsules and the enema formulation of ENTOCORT(R) which is currently marketed in the region by AZ.


With ENTOCORT(R) capsules (budesonide), greatly increased selectivity for the bowel has been achieved. The drug has much higher anti-inflammatory potency than other glucocorticosteroids (GCS), is delivered at the site of inflammation of active Crohn's disease where it acts locally while absorbed, and is subsequently largely metabolised on first pass through the liver. This results in low systemic bioavailability and a highly improved safety profile. Entocort capsules have in recent publications been suggested as first line therapy for management of active CD" (Sandborn/Feagan) ENTOCORT(R) Enema is the drug of choice for both the active phase of distal UC and proctitis, and prolongation of remission. ENTOCORT(R) Enema contains budesonide (2.3 mg) and a vehicle (115 ml).


EDG currently markets PARIET (R)(rabeprazole sodium), a proton pump inhibitor for acid related diseases of the upper GI-tract as well as IMUREK(R) -in cooperation with GlaxoSmithKline-, an immunosuppressive agent approved for autoimmune diseases and IBD indications like Crohn's disease and ulcerative colitis in the gastroenterology therapeutic area, and will now add ENTOCORT(R) with its indication for IBD to EDG's gastroenterology lineup. All three products enable EDG to strengthen its position in theGI therapeutic area through efficient promotion, and Eisai hopes to contribute to improving the quality of life for a wider range of patients.




[ The explanations of companies and terms are attached below for reference ]



<Reference>

[ Eisai GmbH ]
President : Andreas N. Wiegand
Headquarters : Frankfurt, Germany
Establishment : 1996
Capital : 7,669 thousand euros (as of January 31, 2004)
Employees : 112 (including 80 medical representatives)

[AstraZeneca GmbH]
President : Philip Burchard
Headquarters : Wedel, Germany
Establishment : 1953 (since 1999 AZ following the merger of Astra and Zeneca)
Capital : 77,651 thousand euros (as of January 31, 2004)
Employees : 2,300 (including 1,200 medical representatives)


[ Explanation of Terms ]


1. Immunosuppressant

Immunosuppressants are agents that can suppress immune responses, and are used to prevent rejection of transplanted organs as well as to treat allergic reactions and autoimmune diseases.

2. Glucocorticosteroids (GCS)

Steroids are hormones which are produced in the cortex of adrenal gland, and copes with various stress factors. Steroids are synthetic glucocorticosteroid, and effective for ceasing inflammation or immunosuppression.

3. Inflammatory Bowel Disease (IBD)

A group of chronic intestinal diseases of unknown cause which result in inflammation or ulcers in the lining of the large or small intestine. IBD generally refers to ulcerative colitis and Crohn's disease.

i)Ulcerative Colitis (UC)
UC is a diffuse nonspecific disease that causes chronic inflammation of the lining of the colon, frequently leading to erosions or ulcers. The rectum is primarily involved in UC and the inflammation may extend to the whole of the colon. Bloody stool, mucous tool, diarrhea and abdominal pain can be symptoms of UC. This disease characteristically waxes and wanes.

Although the causes of UC are not entirely known, it is currently thought that under the influence of complicatedly linked genetic and environmental factors, the onset and duration of inflammation is probably associated with overreaction of immune cells in the intestine against some kind of antigen.

ii)Crohn's Disease (CD)
CD is an inflammatory disease that is usually diagnosed in persons in their teens or twenties, commonly involving the small and large intestine, but which can affect other parts of the digestive system from the mouth to the anus. The disease may cause elongated or irregular-shaped ulcers, swelling in the lining or narrowing of the inner surface of the bowels. Abdominal pain, diarrhea, fever, and lesions in the anus are common symptoms, but CD can be sometimes associated with complications outside the digestive system.

Although no specific cause has ever been clearly proven, according to recent studies, genetic factors are a probable cause of the disease. This hypothesis ascribes the onset to an abnormal response by immune system cells like lymphocytes against invaders such as food ingredients, foreign subjects, or viruses.